Appealing an IVF Denial: State Mandates, Federal Gaps, and the Letter That Works

The spreadsheet a 34-year-old software engineer in Austin built for her own fertility coverage had three tabs. The first listed the carriers in her employer's open-enrollment menu and what each plan document said about infertility services. The second listed the state mandates in every jurisdiction her company had employees in, with a column for whether the mandate applied to self-funded plans (none of them did). The third listed the cycles she had been told she would need, three by her reproductive endocrinologist's working estimate, at a regional clinic average of roughly $19,800 per fresh cycle plus medications. Her plan document used the word "infertility" in three places: a definition section, an exclusion of "elective infertility services," and a sentence stating that "medically necessary diagnosis of infertility" was covered. Her diagnostic workup had run $4,800 and had returned a finding of diminished ovarian reserve with an anti-Mullerian hormone level of 0.6 ng/mL. The IVF cycle her clinic then scheduled was denied. The reason given was that the procedure fell under the elective-services exclusion. The spreadsheet had predicted that outcome. What the spreadsheet did not yet contain was the appeal.

In-vitro fertilization coverage in the United States sits in a structural gap. The Affordable Care Act does not designate infertility treatment as an essential health benefit; the federal floor is silent. Coverage is largely a function of state insurance law and employer plan design, and a patient's actual access varies by state, by employer, by whether the plan is fully insured or self-funded, and by whether the patient is on TRICARE, Veterans Affairs, Medicaid, or Medicare. RESOLVE: The National Infertility Association tracks 21 states with some form of infertility-coverage mandate as of the 2025 reporting year, of which roughly 15 specifically require IVF coverage in mandated plans. The mandates do not apply uniformly. Self-funded ERISA plans, the majority of large-employer coverage, are preempted from state insurance regulation under 29 USC 1144. A patient on a self-funded plan in a mandate state has the structural posture of a patient in a non-mandate state.

This article walks through which framework actually controls a particular patient's coverage, how the appeal that survives the elective-services exclusion is structured, and where state law and federal gaps create leverage the carrier may not expect.

Three frameworks, layered

The first framework is the plan contract. The Summary Plan Description and the certificate of coverage are the operative documents. They will contain an infertility section, an exclusions section, and a definitions section. The interaction of the three is where most denials live. Carriers routinely cite the exclusions section without addressing whether the definitions or the infertility section override it for medically indicated cases.

The second framework is state insurance law. Twenty-one states have statutes addressing infertility coverage, and the substance varies dramatically. Some states require coverage of IVF by name. Some require coverage of "infertility diagnosis and treatment" without naming the modalities. Some require coverage only for fertility preservation in iatrogenic-infertility cases. Some require coverage of a specified number of cycles. Some impose age caps or marital-status conditions that are themselves now contested under federal anti-discrimination doctrine. The state insurance commissioner's office, indexed at content.naic.org/consumer.htm, is the place to confirm the current text.

The third framework is the federal employment-discrimination and benefit-parity overlays. Pregnancy Discrimination Act jurisprudence has reached infertility coverage in some federal court decisions. Section 1557 of the ACA, codified at 45 CFR Part 92, prohibits discrimination on the basis of sex in federally funded health programs and activities, and the 2024 final rule expanded the discrimination categories. EEOC enforcement positions on fertility benefits have shifted over time. None of these frameworks creates a freestanding right to IVF coverage at the federal level, but several create grounds for appeal in specific factual postures.

Why the elective-services exclusion does not end the discussion

The exclusion language commercial carriers use for IVF typically reads in one of two ways. The narrower form excludes "fertility treatments" generally. The broader form excludes "elective infertility services" or "assisted reproductive technology." Both formulations live in tension with separate plan language requiring coverage of "medically necessary" treatment for diagnosed conditions, and most plan documents define infertility as a medical condition for diagnostic purposes.

The appeal posture is that infertility is a defined medical condition under the plan's own definitions, that the treatment is medically necessary, and that the exclusion was drafted to apply to non-medically-indicated services. Where the patient has a specific diagnosis, diminished ovarian reserve, severe male-factor infertility, tubal-factor infertility, polycystic ovary syndrome with documented anovulation, recurrent pregnancy loss workup findings, the exclusion's "elective" framing strains against the clinical record.

The strength of this argument varies by plan language. Where the exclusion specifically names "in-vitro fertilization" as an excluded service, the argument is weaker and the appeal moves to the state-mandate and federal-overlay grounds. Where the exclusion uses general language, the medical-necessity framing has won at internal and external review with reasonable frequency.

The state mandates, layered into the appeal

The 21 states with infertility-coverage statutes vary in scope. The framework the appeal cites depends on the patient's residence and the plan's regulatory status. The mandates as of the 2025 reporting year, drawing on RESOLVE's tracking and the state insurance code citations, include the following: Arkansas, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Louisiana, Maine, Maryland, Massachusetts, Montana, New Hampshire, New Jersey, New York, Ohio, Rhode Island, Texas, Utah, Washington, and West Virginia. Several additional states have enacted partial mandates limited to fertility preservation for iatrogenic infertility, including states without broader IVF mandates.

The IVF-specific mandates, those requiring coverage of in-vitro fertilization rather than only diagnostic services, include Arkansas, California (with conditions), Colorado, Connecticut, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island, and Utah (with conditions). The specifics vary by state; the patient's actual coverage requires reading the current state statute. The state insurance commissioner is the authoritative source.

Three caveats determine whether the mandate actually helps. First, ERISA self-funded plans are not subject to state insurance mandates. Second, several mandates apply only to group plans of a specified size, typically 50 or more employees, with smaller employers exempted. Third, several mandates contain age caps, cycle caps, or condition-precedent requirements that limit applicability. The appeal cites the mandate language verbatim and applies it to the patient's facts; if the mandate does not apply on its face, the appeal does not gain force from invoking it inaccurately.

The federal coverage map: TRICARE, VA, Medicaid, Medicare

TRICARE coverage of IVF is limited. The Department of Defense covers IVF for active-duty service members with service-connected infertility, under a 2024 policy expansion, and covers diagnostic services more broadly. Coverage for spouses and dependents is more limited. The VA covers IVF for veterans with service-connected infertility under 38 CFR 17.380, with the criteria specified by the Veterans Health Administration. The VA expansion in 2024 broadened eligibility to unmarried veterans and same-sex couples.

State Medicaid coverage of IVF is narrow. The federal Medicaid framework at 42 CFR Part 440 does not require IVF coverage, and most state Medicaid programs do not cover it. New York and Maryland are exceptions in limited scenarios. The Medicaid fair-hearing process under 42 CFR 431.220 is the appeal pathway where coverage is asserted.

Medicare does not cover IVF. The age threshold of Medicare eligibility makes the question rare, but Medicare beneficiaries pursuing IVF are paying privately or through supplemental arrangements.

Exhibit 1: The state IVF-mandate map, as of 2025

The table below summarizes the structural variation. Specific statutory language controls in each case; the state insurance commissioner is the authoritative source.

| State | IVF specifically required | Cycle cap | Common limitations | |---|---|---|---| | Arkansas | Yes | None specified | Lifetime maximum benefit cap | | California | Yes (2024 expansion, group plans) | Subject to plan benefit limits | Phased implementation | | Colorado | Yes | Three completed oocyte retrievals | Group plans only | | Connecticut | Yes | Two cycles | Age cap 40 historically; revised in recent years | | Delaware | Yes | Six retrievals | Group plans | | Hawaii | Yes | One cycle | Conditional on prior infertility duration | | Illinois | Yes | Four oocyte retrievals | Group plans 25+ employees | | Maine | Yes | None specified | Group plans | | Maryland | Yes | Three cycles | Conditions on coverage type | | Massachusetts | Yes | No statutory cap | Conditions on diagnosis | | New Hampshire | Yes | None specified | Group plans | | New Jersey | Yes | Four cycles | Group plans 50+ employees | | New York | Yes (2020 expansion) | Three cycles | Large-group fully insured | | Rhode Island | Yes | None specified | Conditions on age | | Utah | Limited | Conditional | Specific genetic-condition pathway | | Texas | Offer-required, not mandate | n/a | Plans must offer; not required to cover | | Ohio | Diagnostic and limited | n/a | Limited scope | | Louisiana | Limited | n/a | Diagnostic and certain interventions | | Montana | Diagnostic | n/a | Limited scope | | Washington | Diagnostic and fertility preservation | n/a | Limited scope | | West Virginia | Diagnostic | n/a | Limited scope |

Action title for designer: "The state IVF map is patchwork. Three patients with identical clinical facts in three different states will see three different coverage pictures. ERISA self-funded plans see none of it."

Exhibit 2: The plan-regulatory-status diagnostic

Before drafting the appeal, identify which framework actually controls the plan. The four-question diagnostic below sets the posture.

| Question | If yes | If no | |---|---|---| | Is the plan self-funded (employer pays claims directly)? | ERISA governs; state mandates preempted | State law may apply if fully insured | | Is the plan a federal-government plan (FEHB, TRICARE, VA, Medicare)? | Federal coverage rules govern | Commercial or Medicaid frameworks | | Is the plan Medicaid (state managed care)? | State Medicaid manual governs; 42 CFR 431.220 appeal | Commercial/ERISA/FEHB pathways | | Is the plan fully insured by a state-regulated carrier? | State insurance code applies | ERISA/federal preempts |

Action title for designer: "The first question in an IVF appeal is not clinical. It is which body of law actually controls the plan. The answer determines which appeal letter to write."

Exhibit 3: The clinical-necessity argument for diminished ovarian reserve

Diminished ovarian reserve is one of the diagnoses most frequently cited in denied IVF appeals, and the diagnostic and clinical framework supporting medical necessity is well established.

| Element | Source | Use in appeal | |---|---|---| | Diagnostic criteria for DOR | ASRM Practice Committee, Testing and Interpreting Measures of Ovarian Reserve | Establishes diagnosis under generally accepted standard | | AMH and antral follicle count thresholds | ASRM and society consensus | Quantifies the patient's clinical picture | | Treatment indication for IVF in DOR | ASRM Practice Committee guidance on IVF | Connects diagnosis to procedure | | Age-related ovarian decline | ASRM and ACOG joint statements | Supports time-sensitive medical necessity | | Failure of less invasive interventions | Clinical record of IUI attempts where attempted | Supports stepped-care argument | | Outcome data for IVF in DOR | SART CORS national outcomes registry | Supports likelihood of clinical benefit |

Action title for designer: "Diminished ovarian reserve is a defined medical condition with a society-endorsed diagnostic and treatment framework. The medical-necessity argument is well documented; the appeal's job is to cite it cleanly."

Why the deck is procedurally tilted

IVF appeals turn on the interaction of three frameworks (the plan contract's three sections, the state mandate where it applies, and the federal Section 1557 overlay where the denial reflects pattern discrimination) read against the specific clinical diagnosis. The mapped library Apellica has catalogued (more than two hundred carrier-by-denial-type cells, indexed at the bulletin level) each interpret "elective infertility services," "assisted reproductive technology," and "medically necessary infertility diagnosis" differently. The 21 state mandates use materially different statutory language, and self-funded ERISA plans are preempted in mandate states under 29 USC 1144.

The clinical-necessity argument requires the ASRM Practice Committee guidance for the specific diagnosis (diminished ovarian reserve, severe male-factor infertility, tubal-factor, PCOS with anovulation, recurrent pregnancy loss workup findings), the diagnostic basis from the patient's chart, and the alignment to the plan's own definitions section. The 30-day document-request right under 29 CFR 2560.503-1(h)(2)(iii) compels production of the operative bulletin. Procedural exhaustion missteps foreclose external review.

A plan that excludes elective infertility services and covers medically necessary diagnosis of infertility has not excluded the diagnosis. The exclusion is narrower than the denial letter reads.

What the senior-reviewer desk adds

Apellica's reviewers work from a mapped library of over two hundred carrier-by-denial-type cells that tracks IVF coverage at every major commercial carrier, the 21 state mandates by exact statutory language, and the TRICARE/VA fertility-services policy manuals. The desk reads the plan contract's three sections (infertility coverage, exclusions, definitions) in parallel and identifies which clinical diagnosis under ASRM's Practice Committee guidance opens the medical-necessity pathway.

Same-day document-request letters go out with the correct CFR cite. Apellica's senior reviewers build the four-part evidence stack, plan-language citation, clinical facts, peer-reviewed ASRM/ACOG/SART evidence, regulatory hook (plan-contract first, state mandate where it applies, Section 1557 where pattern discrimination is documented), for every case. A senior reviewer reads every appeal before it goes out.

Initial review is free. There is no upfront fee. Patients are not asked to pay anything until the carrier reverses the denial.

The Section 1557 overlay

Section 1557 of the ACA, codified at 45 CFR Part 92, prohibits discrimination in federally funded health programs on the basis of race, color, national origin, sex, age, and disability. The 2024 final rule clarified the scope of "sex" to include sexual orientation and gender identity for relevant purposes and to include pregnancy-related conditions including infertility in some applications. Section 1557 enforcement runs through the HHS Office for Civil Rights, with complaints filed at hhs.gov/ocr.

The 1557 argument is most relevant when the denial pattern is structurally discriminatory, for example a plan that covers fertility treatment for opposite-sex couples but excludes same-sex couples or single individuals. The 2024 rule and subsequent guidance have addressed these patterns directly. An individual coverage denial that is not pattern-discriminatory does not turn on 1557, but where the pattern is present, the OCR complaint runs in parallel with the internal appeal.

TRICARE and VA pathways

TRICARE-covered service members with service-connected infertility have specific pathways through the contractor (Humana Military or TriWest, depending on region) and ultimately through the Defense Health Agency. The criteria are documented in TRICARE policy manuals. Denials are appealable through the standard TRICARE appeal process.

VA-covered veterans access fertility services through the Veterans Health Administration under 38 CFR 17.380, with the 2024 expansion broadening eligibility. Denials run through the VA's internal appeal process. The Board of Veterans' Appeals is the ultimate administrative forum.

These pathways are distinct from commercial appeals. Filing the wrong letter in the wrong forum risks delay and missed deadlines.

Where to ask for help

RESOLVE: The National Infertility Association, at resolve.org, maintains the most comprehensive patient-facing resource on infertility coverage, runs a helpline, and publishes state-mandate summaries. The American Society for Reproductive Medicine, at asrm.org, publishes the clinical Practice Committee guidance that supports medical-necessity arguments. The Society for Assisted Reproductive Technology, at sart.org, maintains the national outcomes registry. The state insurance commissioner, indexed at content.naic.org/consumer.htm, is the source for state-mandate text and external-review filing. The HHS Office for Civil Rights, at hhs.gov/ocr, handles Section 1557 complaints. For ERISA participants, the Department of Labor's Employee Benefits Security Administration is at 1-866-444-3272 or askebsa.dol.gov. Apellica, at apellica.com, prepares evidence-based appeal letters for IVF and infertility denials in all 50 states with no upfront fee.

What to do if you have an IVF denial right now

The state mandates do real work where they apply. The medical-necessity argument does real work everywhere. Most patients leave coverage on the table because the three-framework appeal is more procedural work than they can take on while also coordinating treatment.

The Austin engineer's appeal reframed the cycle as ASRM-guided treatment of diminished ovarian reserve, separating the diagnosis from the elective-services exclusion her plan's definitions section did not actually reach. The first cycle was authorized. The second one was billed under the plan's now-conceded medical-necessity pathway.

The Apellica model, briefly

Apellica prepares the evidence-based appeal letter for IVF and infertility denials in all 50 states, at every level of the internal and external appeal process. The patient reviews and approves every word before submission and authorizes carrier communications under a HIPAA-compliant Assignment of Benefits. We are not a law firm. We are not a medical provider. We are not an insurance carrier. We are an independent administrative service that turns a denied claim into a properly documented appeal letter.

Our model is $0 upfront and a flat fee on successful recovery. If the appeal does not reverse, the patient owes nothing for the preparation work. Coverage extends to all 50 states, every commercial carrier, ERISA plans, TRICARE, VA, and Medicaid. A senior reviewer reads every case before it goes out.

About the author

Mark Henderson works on the senior-reviewer desk at Apellica. The firm prepares insurance-denial appeals for patients across the United States and is headquartered at One World Trade Center, Suite 8500, New York, NY 10007. Apellica does not practice law and the work product is not legal advice. The phone line is +1 (888) 777-6120; the inbox is press@apellica.com; the site is apellica.com.

References

• American Society for Reproductive Medicine, Practice Committee Documents, Testing and Interpreting Measures of Ovarian Reserve.
• American Society for Reproductive Medicine, Practice Committee Documents, Indications for IVF.
• Society for Assisted Reproductive Technology, Clinic Outcome Reporting System (SART CORS).
• RESOLVE: The National Infertility Association, Insurance Coverage by State.
• 29 USC 1144. ERISA preemption.
• 29 CFR 2560.503-1. ERISA claims procedure.
• 45 CFR 147.136. Internal claims and appeals and external review.
• 45 CFR Part 92. ACA Section 1557 nondiscrimination regulations.
• 38 CFR 17.380. VA assisted reproductive technology services.
• 42 CFR Part 440. Medicaid services framework.
• 42 CFR 431.220. Medicaid fair-hearing procedures.
• TRICARE policy manuals, assisted reproductive technology coverage.
• HHS Office for Civil Rights. hhs.gov/ocr.
• Department of Labor, Employee Benefits Security Administration. askebsa.dol.gov.
• NAIC Consumer Information Source. content.naic.org/consumer.htm.